Market Dynamics In 2021, the global market for axial spondylarthritis treatment exhibited significant strength and is anticipated to sustain a rapid revenue compound annual growth rate (CAGR) throughout the forecast period. The escalating prevalence of axial spondylarthritis among males in their late teens and early twenties is propelling the market's revenue expansion. Additionally, favorable conditions for pharmaceutical producers and increased attention from various authorities aimed at improving the existing healthcare infrastructure are contributing to this growth. However, the limited treatment options and high treatment costs are impeding revenue growth in the market.read full report: [URL]https://www.reportsanddata.com/report-detail/axial-spondylarthritis-market[/URL]
Spondylarthritis (SpA) encompasses a group of chronic inflammatory autoimmune diseases characterized by specific clinical and genetic features. It primarily affects the joints of the spine and, in some instances, the extremities.
Factors Supporting Market Growth Drivers: Several factors are contributing to the revenue growth of the axial spondylarthritis market. The prevalence of axSpA in the U.S. population (0.9-1.4%) exceeds the prevalence at diagnosis (0.2-0.7%). Axial spondylarthritis, the most prevalent type of arthritis, is expected to become even more prevalent with increasing life expectancy and obesity rates. Moreover, the rising incidence of eye inflammation such as Uveitis and inflammatory back pains is driving market revenue growth. This disorder predominantly affects the male population, with males accounting for 3,970 million or 50.42% of the global population, indicating 65.51 million more men than women worldwide. These factors contribute to revenue growth in the axial spondylarthritis market.
Restraints: Patients with axial spondylarthritis often experience adverse effects from treatment regimens. The condition's pain is frequently managed with nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids, both over-the-counter and prescription. However, the use of NSAIDs has been associated with an increased risk of heart attacks and strokes, while corticosteroids' use was limited during the COVID-19 pandemic, as per World Health Organization guidelines advising against systemic corticosteroid use in severe acute respiratory infection cases related to Coronavirus.
Key Market Trends and Innovations: Ongoing studies and trials, such as the Double-Blind, Multicenter, International, Randomized Placebo-Controlled Study testing the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of BCD-180 in Patients with Axial Spondyloarthritis, and the assessment of the preliminary efficacy, safety, pharmacokinetics, and immunogenicity of GR1501 injection (IL-17A antibody) in a phase II clinical trial, indicate promising advancements in treatment options.
Competitive Landscape: Companies in the market, including Johnson & Johnson Private Limited, Pfizer, Abbott Laboratories, Teva Pharmaceuticals, and others, are adopting both organic and inorganic strategies to strengthen their market presence.
Get a sample copy of the Axial Spondylarthritis Market report: [FURL]https://www.reportsanddata.com/download-free-sample/5503[/FURL]